TEM · Tempus AI, Inc.
$42.69
-0.02% last session
End-of-day data · updated 2026-07-28
Market cap
$8B
Enterprise value
$8B
Trailing P/E
—
Forward P/E
-542.0
Dividend yield
—
Beta
3.46
Avg volume
6M
Employees
4K
2D change
0.52%
5D change
-6.74%
10D change
-18.22%
30D change
-23.57%
60D change
-14.98%
MTD change
-30.34%
YTD change
-27.33%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — TEM
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-20
Latest call per bank · past 12 months
Jefferies
Underperform$35.00
-18.0% vs priceMorgan Stanley
Overweight$70.00
+64.0% vs priceJP Morgan
Neutral$60.00
+40.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-20 | Needham | Reiterates | Buy | $75.00 |
| 2026-07-16 | Guggenheim | Maintains | Buy | $60.00 → $65.00 |
| 2026-07-01 | Freedom Capital Markets | Initiates | Hold | $0.00 → $59.00 |
| 2026-06-01 | Needham | Reiterates | Buy | $75.00 |
| 2026-06-01 | BTIG | Reiterates | Buy | $80.00 |
| 2026-05-11 | HC Wainwright & Co. | Maintains | Buy | $95.00 → $64.00 |
| 2026-05-08 | BTIG | Maintains | Buy | $90.00 → $80.00 |
| 2026-05-06 | TD Cowen | Maintains | Buy | $65.00 → $68.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 33 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 16.0% below the 50-day MA ($51.09).
- Price vs 200-day MA: Trading 28.7% below the 200-day MA ($60.20).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-1.77) — short-term momentum is fading.
- 52-week range: Price is within 10% of the 52-week low ($42.37).
TEM Price Chart
Loading chart for TEM…
Fundamentals
About Tempus AI, Inc.
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
More in Health Information Services
VEEV
Veeva Systems Inc.
$32B -12.9% YTD
BTSG
BrightSpring Health Services, I
$14B 92.2% YTD
HQY
HealthEquity, Inc.
$8B 8.1% YTD
HNGE
Hinge Health, Inc.
$6B 61.7% YTD
TXG
10x Genomics, Inc.
$6B 181.5% YTD
DOCS
Doximity, Inc.
$4B -52.6% YTD
WAY
Waystar Holding Corp.
$4B -29.4% YTD
PRVA
Privia Health Group, Inc.
$3B 4.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.